Materias dentro de su búsqueda.
Mostrando 21 - 38 Resultados de 38 Para Buscar '"Vedānta"', tiempo de consulta: 0.08s Limitar resultados
  1. 21
    “…DISCLOSURES: Rajita Menon, PhD, Vedanta Biosciences: Patent inventor|Vedanta Biosciences: I am employed by Vedanta Biosciences.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2140. Biological Features of Response to VE303, a Defined Bacterial Consortium, in Patients with Clostridioides difficile Infection (CDI): Results from the Phase 2 CONSORTIUM Study
  2. 22
    “…Kuijper, Prof. Dr., Vedanta Biosciences: Advisor/Consultant Silvia Caballero, PhD, Vedanta Biosciences: Advisor/Consultant|Vedanta Biosciences: Board Member|Vedanta Biosciences: Ownership Interest…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2760. Fecal Microbiota Transplantation for Decolonization of Carbapenemase-Producing Enterobacterales
  3. 23
    por Jagannadham, Medicharla Venkata
    Publicado 2016
    “…The explanation for Vedanta offered by Bhakti Niskama Santa (BNS)(1) is valid from both scientific and philosophical grounds. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Vendantic view on life and consciousness: BN Shanta is correct
  4. 24
    Publicado 2008
    Video VHS
    Yoga = Sivananda yoga video : una guía completa de posturas, ejercicios de respiración, relajación y meditación basados en una técnica de la yoga Sivananda.
  5. 25
    por Yati, Guru Nitya Chaityanya
    Publicado 1992
    “…It also has the potential of giving rise to a new psychotherapy in which devices of bhakti, yoga and Vedanta can be ably incorporated.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    AYURVEDA – A HOLISTIC SCIENCE
  6. 26
    “…Wortman, MS, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Barbara McGovern, MD, Seres Therapeutics: Stocks/Bonds Brooke Hasson, PhD, Sage Therapeutics: Stocks/Bonds|Seres Therapeutics: Stocks/Bonds Dina Hot, PhD, Aimmune Therapeutics: Employee Darrell Pardi, MD, Abbvie: Advisor/Consultant|AMT: Grant/Research Support|BI: Advisor/Consultant|Immunic: Advisor/Consultant|Rise: Advisor/Consultant|Seres Therapeutics: Advisor/Consultant|Seres Therapeutics: Grant/Research Support|Summit: Advisor/Consultant|Takeda: Grant/Research Support|Vedanta: Advisor/Consultant|Vedanta: Grant/Research Support Christopher Ford, PhD, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Matthew Henn, PhD, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    655. Analysis of Microbiome Diversity and Secondary Bile Acid Synthesis Following SER-109 or Placebo in Patients with First Recurrent or Multiply Recurrent Clostridioides difficile Infection
  7. 27
    por Meling, Daniel
    Publicado 2022
    “…While several contemplative traditions, such as Zen, Mahāmudrā, Dzogchen, and Advaita Vedanta emphasize the importance of such a non-dual insight for the cultivation of genuine wellbeing, only very few attempts in contemplative science have turned toward the study of non-dual-oriented practices. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Knowing the Knowing. Non-dual Meditative Practice From an Enactive Perspective
  8. 28
    por Shanta, Bhakti Niskama
    Publicado 2015
    “…In contrast to the idea of objective evolution of bodies, as envisioned by Darwin and followers, Vedānta advocates the idea of subjective evolution of consciousness as the developing principle of the world. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Life and consciousness – The Vedāntic view
  9. 29
    “…Young, MD/PhD, ASM: Senior Editor|Debiopharm: Advisor/Consultant|Vedanta Biosciences: Advisor/Consultant…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2957. Decreased microbial diversity and baseline intestinal inflammation are associated with worse outcome in aged, female mice infected with Clostridioides difficile
  10. 30
    “…Gonzales-Luna, PharmD, BCIDP, Cidara Therapeutics: Grant/Research Support|Ferring Pharmaceuticals: Personal Fees|Paratek Pharmaceuticals: Grant/Research Support|Seres Therapeutics: Grant/Research Support Kevin Garey, PharmD, MS, BCIDP, Acurx Pharmaceuticals: Grant/Research Support|Cidara Therapeutics: Grant/Research Support|Ferring Pharmaceuticals: Advisor/Consultant|Paratek Pharmaceuticals: Grant/Research Support|Seres Therapeutics: Grant/Research Support|Vedanta Therapeutics: Grant/Research Support…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    682. Novel rpoB mutations and trends in clinical Clostridioides difficile isolates with reduced fidaxomicin susceptibility
  11. 31
    “…Louie, MD, Artugen: Advisor/Consultant|Artugen: Grant/Research Support|Crestone: Advisor/Consultant|Crestone: Grant/Research Support|Finch Therapeutics: Advisor/Consultant|Finch Therapeutics: Grant/Research Support|Rebiotix: Advisor/Consultant|Rebiotix: Grant/Research Support|Seres Therapeutics: Advisor/Consultant|Seres Therapeutics: Grant/Research Support|summit plc: Advisor/Consultant|summit plc: Grant/Research Support|Vedanta Biosciences: Advisor/Consultant|Vedanta Biosciences: Grant/Research Support Maria Vehreschild, Prof. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    221. Assessment and Proposed Revision of Clinical Trial Clostridioides difficile Infection Clinical Response and Outcomes Definitions
  12. 32
    “…Young, MD/PhD, ASM: Senior Editor|Debiopharm: Advisor/Consultant|Vedanta Biosciences: Advisor/Consultant…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2956. Increased Microbiota Alpha Diversity is Associated with Decreased Hospital Mortality in Medical Intensive Care Unit Patients
  13. 33
    “…Summit: Consultant, Consulting fee. Vedanta: Consultant, Consulting fee. D. N. Gerding, Merck: Scientific Advisor, Consulting fee. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    976. Clostridium difficile Colonization Molecular Epidemiology and Anti-toxin Serological Responses in Healthy Infants: A Prospective Cohort Study
  14. 34
    “…Alonso, MD, FIDSA, Alnylam Pharmaceuticals (Employee)Merck (Research Grant or Support) Ciarán Kelly, MD, Artugen (Consultant)Facile Therapeutics (Consultant)Finch (Consultant)First Light Biosciences (Consultant)Matrivax (Consultant)Merck (Consultant)Vedanta (Consultant)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    645. Absence of Toxemia in Clostridioides difficile infection: Results from Ultrasensitive Toxin Assay of Serum
  15. 35
    “…DISCLOSURES: Akiko Iwasaki, PhD, 4Bio (Consultant, Advisor or Review Panel member)Adaptive Biotechnologies (Consultant, Advisor or Review Panel member)Blavatnik (Grant/Research Support)HHMI (Grant/Research Support)Mathers (Grant/Research Support)NIH (Grant/Research Support)Spring Discovery (Grant/Research Support)Spring Discovery (Consultant, Advisor or Review Panel member)Vedanta InProTher (Consultant, Advisor or Review Panel member)Yale School of Medicine (Grant/Research Support) Nathan D. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    301. Detection of Pneumococcal Pneumonia During SARS-CoV-2 Infection
  16. 36
    “…Gonzales-Luna, PharmD, BCIDP, Cidara Therapeutics: Grant/Research Support|Ferring Pharmaceuticals: Personal Fees|Paratek Pharmaceuticals: Grant/Research Support|Seres Therapeutics: Grant/Research Support Yoav Golan, MD, Ferring Pharmaceuticals: Advisor/Consultant|Pfizer: Honoraria|Seres Therapeutics: Advisor/Consultant|Vedanta Bioscience: Advisor/Consultant Carolyn D. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    702. Efficacy of Fecal Microbiota, Live-jslm After Receipt of Non–Clostridioides difficile Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Trial
  17. 37
    “…DISCLOSURES: Matthew Sims, MD, PhD, FACP, FIDSA, Astra Zeneca (Independent Contractor)Diasorin Molecular (Independent Contractor)Epigenomics Inc (Independent Contractor)Finch (Independent Contractor)Genentech (Independent Contractor)Janssen Pharmaceuticals NV (Independent Contractor)Kinevant Sciences gmBH (Independent Contractor)Leonard-Meron Biosciences (Independent Contractor)Merck and Co (Independent Contractor)OpGen (Independent Contractor)Prenosis (Independent Contractor)Regeneron Pharmaceuticals Inc (Independent Contractor)Seres Therapeutics Inc (Independent Contractor)Shire (Independent Contractor)Summit Therapeutics (Independent Contractor) Sahil Khanna, MBBS, MS, Seres (Grant/Research Support) Darrell Pardi, MD, seres (Consultant)Vedanta (Consultant) Paul Feuerstadt, MD, FACG, Ferring/Rebiotix Pharmaceuticals (Consultant, Scientific Research Study Investigator, Speaker's Bureau)Finch Pharmaceuticals (Scientific Research Study Investigator)Merck and Co (Speaker's Bureau)SERES Therapeutics (Consultant, Scientific Research Study Investigator)Takeda Pharmaceuticals (Consultant) Elaine E. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    658. Diagnostic Testing Among Patients with Suspected Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III a Phase 3 Clinical Trial: Implications for Clinical Practice vs Clinical Trials
  18. 38
    “…Young, MD, PhD, American Society for Microbiology (Other Financial or Material Support, Senior Editor for mSphere)Vedanta Biosciences (Consultant) Krishna Rao, MD, MS, Bio-K+ International, Inc. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    17. Comparative Assessment of a Machine Learning Model and Rectal Swab Surveillance to Predict Hospital Onset Clostridioides difficile
Herramientas de búsqueda: RSS